Re: 70% success rate
in response to
by
Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.
Message: Re: 70% success rate
Makes him neither
Pubpat can claim success when they get a nuance changed. Pohl can still claim success if the patent remains fundamentally unchanged.
Victory for all, one side far more hollow.
Regards
Loading...
Loading...
Apr 17, 2007 05:26PM
Apr 17, 2007 05:35PM
Apr 17, 2007 05:52PM
Apr 17, 2007 05:54PM
Apr 17, 2007 05:58PM
Apr 17, 2007 07:05PM
Apr 17, 2007 08:14PM
Apr 17, 2007 08:34PM
Apr 17, 2007 08:38PM
Apr 17, 2007 08:52PM
Apr 18, 2007 04:04AM
New Message
Please
login
to post a reply